Lead reduces tension development and the myosin ATPase activity of the rat right ventricular myocardium

Brazilian Journal of Medical and Biological Research

Volumn 41, Issue 9, 2008, Pages 789-795

  Vassallo, D V ^a,b   Lebarch, E C ^a   Moreira, C M ^a   Wiggers, G A ^a   Stefanon, I ^a,b  

^a FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

^b Escola de Ciências Superiores da Santa Casa de Misericórdia do Espírito Santo   (Brazil)

Author keywords

Contraction; Heart; Lead; Myosin ATPase activity; Right ventricular strips

Indexed keywords

CAFFEINE; CALCIUM ION; CONTRACTILE PROTEIN; ISOPRENALINE; LEAD ACETATE; MYOSIN ADENOSINE TRIPHOSPHATASE;

ANIMAL TISSUE; ARTICLE; CALCIUM TRANSPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; HEART MUSCLE CONTRACTILE FORCE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE TENSION; HEART RIGHT VENTRICLE; HEART VENTRICLE CONTRACTILITY; INOTROPISM; MALE; MUSCLE ISOMETRIC CONTRACTION; MUSCLE TETANIC CONTRACTION; NONHUMAN; RAT; SARCOLEMMA; SARCOPLASMIC RETICULUM; WISTAR RAT;

RATTUS; RATTUS NORVEGICUS;

EID: 54349104551     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2008000900008     Document Type: Article

References (37)

1. Nriagu JO. Satumine gout among Roman aristocrats. Did lead poisoning contribute to the fall of the Empire? N Engl J Med 1983; 308: 660-663.
2. Gilfillan SC. Lead poisoning and the fall of Rome. J Occup Med 1965; 7: 53-60.
3. World Health Organization. Environmental health criteria 165: inorganic lead. In: WHO (Editor), International Programme on Chemical Safety (IPCS). Geneve: 1995.
4. Patrick L. Lead toxicity part II: the role of free radical damage and the use of antioxidants in the pathology and treatment of lead toxicity. Altem Med Rev 2006; 11: 114-127.
5. Lustberg M, Silbergeld E. Blood lead levels and mortality. Arch Intern Med 2002; 162: 2443-2449.
6. Harlan WR. The relationship of blood lead levels to blood pressure in the U.S. population. Environ Health Perspect 1988; 78: 9-13.
7. Navas-Acien A, Guallar E, Silbergeld EK, Rothenberg SJ. Lead exposure and cardiovascular disease - a systematic review. Environ Health Perspect 2007; 115: 472-482.
8. Vupputuri S, He J, Muntner P, Bazzano LA, Whelton PK, Batuman V. Blood lead level is associated with elevated blood pressure in blacks. Hypertension 2003; 41: 463-468.
9. Weiler E, Khalil-Manesh F, Gonick HC. Effects of lead and a low-molecular-weight endogenous plasma inhibitor on the kinetics of sodium-potassium-activated adenosine triphosphatase and potassium-activated p-nitrophenylphosphatase. Clin Sci 1990; 79: 185-192.
10. Khalil-Manesh F, Gonick HC, Weiler EW, Prins B, Weber MA, Purdy RE. Lead-induced hypertension: possible role of endothelial factors. Am J Hypertens 1993; 6: 723-729.
11. Carmignani M, Volpe AR, Boscolo P, Qiao N, Di Gioacchino M, Grilli A, et al. Catecholamine and nitric oxide systems as targets of chronic lead exposure in inducing selective functional impairment. Life Sci 2000; 68: 401-415.
12. Vaziri ND, Ding Y, Ni Z. Compensatory up-regulation of nitric-oxide synthase isoforms in lead-induced hypertension; reversal by a superoxide dismutase-mimetic drug. J Pharmacol Exp Ther 2001; 298: 679-685.
13. Farmand F, Ehdaie A, Roberts CK, Sindhu RK. Lead-induced dysregulation of superoxide dismutases, catalase, glutathione peroxidase, and guanylate cyclase. Environ Res 2005; 98: 33-39.
14. Boscolo P, Carmignani M, Carelli G, Finelli VN, Giuliano G. Zinc and copper in tissues of rats with blood hypertension induced by long-term lead exposure. Toxicol Lett 1992; 63: 135-139.
15. Carmignani M, Boscolo P, Poma A, Volpe AR. Kininergic system and arterial hypertension following chronic exposure to inorganic lead. Immunopharmacology 1999; 44: 105-110.
16. Williams BJ, Hejtmancik MR Jr, Abreu M. Cardiac effects of lead. Fed Proc 1983; 42: 2989-2993.
17. Prentice RC, Kopp SJ. Cardiotoxicity of lead at various perfusate calcium concentrations: functional and metabolic responses of the perfused rat heart. Toxicol Appl Pharmacol 1985; 81: 491-501.
18. 2+ channels requires treatment with heavy metal antidotes. J Pharmacol Exp Ther 1997; 282: 172-180.
19. Vassallo DV, Lima EQ, Campagnaro P, Stefanon I, Leite CM, Mill JG. Effects of isoproterenol on the mechanical activity of isolated papillary muscles and perfused rat hearts in various calcium concentrations. Pharmacol Res 1994; 29: 251-260.
20. Delcayre C, Swynghedauw B. A comparative study of heart myosin ATPase and light subunits from different species. Pflugers Arch 1975; 355: 39-47.
21. Cappelli V, Bottinelli R, Poggepi C, Moggio R, Reggiani C. Shortening velocity and myosin and myofibrillar ATPase activity related to myosin isoenzyme compositing during postnatal development in rat myocardium. Circ Res 1989; 65: 446-457.
22. Bremel RD, Weber A. Calcium binding to rabbit skeletal myosin under physiological conditions. Biochim, Biophys Acta 1975; 376: 366-374.
23. 2+-stimulated ATPase activity. Anal Biochem 1986; 157: 375-380.
24. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
25. Stohs SJ, Bagchi D. Oxidative mechanisms in the toxicity of metal ions. Free Radic Biol Med 1995; 18: 321-336.
26. Vaziri ND. Pathogenesis of lead-induced hypertension: role of oxidative stress. J Hypertens Suppl 2002; 20: S15-S20.
27. Flink IL, Rader JH, Banerjee SK, Morkin E. Atrial and ventricular cardiac myosins contain different heavy chain species. FEBS Lett 1978; 94: 125-130.
28. Anner BM, Moosmayer M, Imesch E. Mercury blocks Na-K-ATPase by a ligand-dependent and reversible mechanism. Am J Physiol 1992; 262: F830-F836.
29. Moreira CM, Oliveira EM, Bonan CD, Sarkis JJ, Vassallo DV. Effects of mercury on myosin ATPase in the ventricular myocardium of the rat. Comp Biochem Physiol C Toxicol Pharmacol 2003; 135C: 269-275.
30. 2+] in tetanized mammalian heart muscle. J Gen Physiol 1986; 87: 223-242.
31. Leite CM, Vassallo DV, Mill JG. Characteristics of tetanic contractions in caffeine-treated rat myocardium. Can J Physiol Pharmacol 1995; 73: 638-643.
32. Bassani JW, Bassani RA, Bers DM, Relaxation in rabbit and rat cardiac cells: species-dependent differences in cellular mechanisms. J Physiol 1994; 476: 279-293.
33. Aronson RS. Characteristics of action potentials of hypertrophied myocardium from rats with renal hypertension. Circ Res 1980; 47: 443-454.
34. Marban E, Wier WG. Ryanodine as a tool to determine the contributions of calcium entry and calcium release to the calcium transient and contraction of cardiac Purkinje fibers. Circ Res 1985; 56: 133-138.
35. 2+ release from sarcoplasmic reticulum. J Biol Chem 1988; 263: 18785-18792.
36. Oliveira EM, Vassallo DV, Sarkis JJ, Mill JG. Mercury effects on the contractile activity of isolated heart muscle. Toxicol Appl Pharmacol 1994; 128: 86-91.
37. Bers DM. Cardiac excitation-contraction coupling. Nature 2002; 415: 198-205.